• Group sales up 9% in local currencies to 12.2 billion Swiss francs in first three months (+6% in Swiss
francs, +15% in US dollars).
• Both divisions continue to outgrow their respective markets in 2010 1.
• Roche confirms full-year outlook.
Sales in millions of CHF Three months ended 31 March % change
2010 2009 In CHF In LC* In USD
Pharmaceuticals Division 9,727 9,216 +6 +10 +15
United States 3,647 3,586 +2 +10 +10
Western Europe 2,597 2,532 +3 +4 +11
Japan 988 1,139 -13 -9 -6
International** 2,495 1,959 +27 +25 +38
Diagnostics Division 2,518 2,361 +7 +9 +16
Roche Group 12,245 11,577 +6 +9 +15
*LC= local currencies
**International: Asia–Pacific, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), Latin
America, Canada, Others
See appendix to this media release for details of quarterly sales growth

Pharmaceuticals Division posts double-digit growth in first quarter
• Pharma sales grow 10% (6% in Swiss francs, 15% in US dollars)
• Continued strong growth of oncology portfolio, increasing 12% in local currencies; sales of leading
cancer medication Avastin advance 18%.
• Promising US launch of Actemra for rheumatoid arthritis
• Rituxan approved in US for chronic lymphocytic leukemia, the most common form of adult leukemia
• US marketing application for T–DM1 for advanced HER2-positive breast cancer to be brought forward
to 2010, based on strong phase II results
Diagnostics Division continues to significantly outperform the market
• Divisional sales grow 9% (7% in Swiss francs, 16% in US dollars), again substantially ahead of the global
market, driven by Professional Diagnostics, Diabetes Care and Applied Science
• Continued strong uptake of recently launched products in Diabetes Care (Accu-Chek Mobile, Accu-
Chek Combo) as well as other business areas (cobas 8000, cobas 4800 and xCELLigence systems)

Barring unforeseen events.
1 Unless otherwise stated, all growth rates are in local currencies

Commenting on the Group’s first-quarter sales figures, Roche CEO Severin Schwan said: ‘With sales
advancing 9%, Roche is off to a very good start in 2010. Both divisions continued to outgrow their respective
markets. We are thus fully on track for 2010.’ Referring to Roche’s strong late-stage pipeline, Schwan added:
‘I am very pleased that, after discussions with the FDA, we are now planning to submit a US marketing
application for our innovative breast cancer treatment T–DM1 this year, based on strong phase II data in
women who have not responded to prior treatments.’
Roche Group
Strong sales growth in first quarter
The Roche Group sustained its strong sales growth in the first three months of 2010. Group sales grew 9% in
local currencies (6% in Swiss francs; 15% in US dollars) to 12.2 billion Swiss francs. The Pharmaceuticals
Division’s sales increased 10% in local currencies (6% in Swiss francs; 15% in US dollars) to 9.7 billion Swiss
francs, maintaining its above-market growth. The Diagnostics Division also maintained its above-market
growth, with sales increasing 9% in local currencies (7% in Swiss francs; 16% in US dollars) to 2.5 billion
Swiss francs.
At its Investor Day in March, Roche provided an in-depth review of its near- and long-term growth
opportunities. Roche plans to introduce at least six new medicines by the end 2014. Of the 61 new molecular
entities (NMEs) in the Group’s R&D pipeline, ten are currently in late-stage development, and Roche plans
to increase this to as many as 13 NMEs by year end. The Group’s late-stage pipeline also comprises more than
35 new indications for existing products. Roche is set to strengthen its global leadership position in oncology
and to expand in therapeutic areas such as metabolism, inflammation and diseases of the central nervous
system.
In the first quarter Roche continued to pay down the debt raised to finance the Genentech transaction:
3 billion US dollars and 1.5 billion Euros were repaid as scheduled.
Outlook
Based on its first-quarter sales, Roche confirms its full-year outlook for 2010. Barring unforeseen events,
Roche expects sales in 2010 for the Pharmaceuticals Division and for the Group to increase in the mid-singledigit
range in local currencies (excluding Tamiflu). In the Diagnostics Division, full-year sales are expected to
grow significantly ahead of the market. Despite an anticipated decrease in Tamiflu sales from 3.2 to 1.2 billion Swiss Francs, Roche is aiming to achieve double-digit Core Earnings per Share growth at constant
exchange rates. In addition, by the end of the year Roche expects to have repaid a quarter of the debt raised to
finance the Genentech transaction.

For more information: www.roche.com